Up to 30% of human immunodeficiency virus (HIV)–infected patients who are receiving long-
term highly active antiretroviral therapy do not exhibit a marked increase in the CD4+ T cell …

HAART in HIV-1-infected individuals has a broad spectrum of clinical outcomes. In the
majority of patients, plasma viral load becomes undetectable and CD4+ T-cells increase …

Background The optimal time for the initiation of antiretroviral therapy for asymptomatic
patients with human immunodeficiency virus (HIV) infection is uncertain. Methods We …

Background. Sustained suppression of the human immunodeficiency virus (HIV) type 1 RNA
load with the use of highly active antiretroviral therapy (HAART) results in immunologic …

Objective To provide updated estimates of the prevalence and clinical impact of human
immunodeficiency virus− associated sensory neuropathy (HIV-SN) and neuropathic pain …

HIV infection results in CD4+ T cell deficiency, but efficient combination antiretroviral therapy
(c-ART) restores T cells and decreases morbidity and mortality. However, immune …

Background. It is estimated that 10%–25% of patients who start highly active antiretroviral
therapy (HAART) experience immune reconstitution inflammatory syndrome (IRIS). Our …

Background. Some human immunodeficiency virus (HIV)–infected individuals initiating
combination antiretroviral therapy (cART) with low CD4 counts achieve viral suppression but …

Objective: To provide information on responses to combination antiretroviral therapy in
children, adolescents and older HIV-infected persons. Design and setting: Multicohort …

Objective: To study immunologic and clinical responses to HAART in patients over 50 years
old. Design and methods: A prospective cohort study which included 68 hospitals in France …